Ascendis Pharma (ASND) EVP details warrants and RSU holdings

Rhea-AI Filing Summary

Ascendis Pharma A/S executive Anni Lotte Kirstine Sonderbjerg Pedersen has filed an initial Form 3 detailing her equity holdings. She directly owns 19,460 Ordinary Shares. In addition, she holds several series of fully vested, currently exercisable warrants over 20,000, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares with exercise prices ranging from 37.1800 to 176.2800 and expirations between 2027 and 2031.

She also holds Restricted Stock Units over 4,246, 6,394 and 9,552 underlying Ordinary Shares. Footnotes state that certain RSUs vest on March 1, 2027, with others vesting in two or three equal annual installments beginning on that date, and each RSU represents a contingent right to receive one American Depositary Share, with each ADS representing one Ordinary Share. The filing reports holdings only, with no purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Admin Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	19,460	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	12/12/2027	Ordinary Shares	20,000	$37.18	D
Warrants	(2)	12/11/2028	Ordinary Shares	45,000	$62.17	D
Warrants	(2)	12/10/2029	Ordinary Shares	27,000	$108	D
Warrants	(2)	12/10/2030	Ordinary Shares	22,755	$176.28	D
Warrants	(2)	12/09/2031	Ordinary Shares	14,504	$139.65	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	4,246	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	6,394	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	9,552	(4)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants are fully vested and currently exercisable.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Lotte Sonderbjerg	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Ascendis Pharma (ASND) Form 3 for Anni Pedersen show?

The Form 3 shows Anni Pedersen’s initial beneficial ownership in Ascendis Pharma. It lists her direct Ordinary Share holdings, multiple fully vested warrants with future expiration dates, and several Restricted Stock Unit awards that convert into American Depositary Shares over time.

How many Ascendis Pharma (ASND) Ordinary Shares does Anni Pedersen directly own?

Anni Pedersen directly owns 19,460 Ascendis Pharma Ordinary Shares. This direct stake is separate from her derivative positions, which include warrants and Restricted Stock Units that may convert into additional shares or American Depositary Shares in the future as they vest or are exercised.

What warrant holdings are disclosed for Anni Pedersen in Ascendis Pharma (ASND)?

She holds several fully vested, currently exercisable warrants over specific Ordinary Share amounts. These cover 20,000, 45,000, 27,000, 22,755 and 14,504 underlying shares with exercise prices from 37.1800 to 176.2800, expiring on various dates between 2027 and 2031.

What Restricted Stock Units does Anni Pedersen hold in Ascendis Pharma (ASND)?

She holds RSUs over 4,246, 6,394 and 9,552 underlying Ordinary Shares. Footnotes explain that these RSUs vest on or beginning March 1, 2027 in one, two, or three annual installments, and each RSU represents a contingent right to receive one American Depositary Share.

Are Anni Pedersen’s warrants in Ascendis Pharma (ASND) currently exercisable?

Yes, the filing states the warrants are fully vested and currently exercisable. This means she can choose to convert those warrants into Ordinary Shares at their stated exercise prices any time before their respective expiration dates between 2027 and 2031.

How do Ascendis Pharma (ASND) RSUs relate to American Depositary Shares?

Each Restricted Stock Unit represents a contingent right to receive one ADS. Footnotes clarify that each American Depositary Share corresponds to one Ordinary Share, so vested RSUs can effectively deliver one ADS, mirroring one underlying Ordinary Share in Ascendis Pharma.